Recently, preliminary results of the OLAGLI trial investigating olaparib in 35 patients with recurrent IDH1/2mt high-grade contrast-enhancing gliomas were presented at American Society of Clinical Oncology 2021 (33). The gene discussed is IDH1; the disease is central nervous system cancer.